139 filings
Page 2 of 7
DEFA14A
9pj kas0t9
5 Apr 23
Additional proxy soliciting materials
7:18am
S-8
kcicbqdhvrce 10b
23 Mar 23
Registration of securities for employees
4:36pm
8-K
e7qc 8pihclea
23 Mar 23
Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates
4:07pm
8-K
nll0c 8azvld
6 Jan 23
Entry into a Material Definitive Agreement
5:30pm
424B5
v4og74cigqfmxeq
6 Jan 23
Prospectus supplement for primary offering
5:28pm
8-K
ag9ms un4qdu726p6el
18 Nov 22
Amendments to Articles of Incorporation or Bylaws
4:05pm
8-K
rgez2swvw545zk
10 Nov 22
Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
4:11pm
8-K
yk589di
17 Oct 22
Results support potential clinically meaningful activity of fosgonimeton without background therapy and mitigate program risk
8:30am
8-K
qyjh9n1rruqrsog33iw
15 Aug 22
Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
4:35pm
8-K
eger2t68vfg54bz
22 Jun 22
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
7:05am
8-K
q6z3daho8pj5f
24 May 22
Submission of Matters to a Vote of Security Holders
5:01pm
DEFA14A
vjwb47f6et9byox
17 May 22
Additional proxy soliciting materials
6:06am
DEFA14A
qxweu k78nya1h27
16 May 22
Additional proxy soliciting materials
6:32pm
DFAN14A
ftwd2qh29y336v w0h9
16 May 22
Additional proxy materials by non-management
2:04pm
8-K
pz83x2
12 May 22
Athira Pharma Reports First Quarter 2022 Financial Results
4:12pm